Christina Washington is an Oncology physician affiliated with Oklahoma City University. OpenAlex indexes 99 publications with 317 citations (h-index 10); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
800 NE 10th St Ste 5050
Oklahoma City, OK 731045418
Telephone
405-271-8707Provider last certified this registry record 19 May 2022.
Clinical trials
- Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)
Sponsor: University of Oklahoma
- A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
Sponsor: University of Oklahoma
- Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
Sponsor: University of Oklahoma
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20257 payments
- ABBVIE INC.Program year20256 payments
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
35.4%Opioid Agonist13.4%Oxycodone Hcl100%Part D≥15 patientsPhenothiazine9.5%Prochlorperazine Maleate100%Part D≥20 patients+ 2 more classes in this area
Cancer & immunology
21.4%Poly(ADP-Ribose) Polymerase Inhibitor12.3%Lynparza55%Zejula46%Part D<11 patientsAromatase Inhibitor5.3%Letrozole100%Part D<11 patients+ 1 more class in this area
Genitourinary & hormones
15.3%Progestin7.8%Megestrol Acetate100%Part D<11 patientsEstrogen7.5%Estradiol (Once Weekly)59%Estradiol41%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Overall survival by histologic subtype within the molecular classification of endometrial cancer
Gynecologic Oncology
2026 - Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study
International Journal of Gynecological Cancer
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Christopher Graffeo, MD
Oklahoma City University
Timothy Mapstone, MD
Oklahoma City University
Sami Ibrahimi, MD
Oklahoma City University
Hakeem Shakir
Oklahoma City University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”